New pill shows promise for tough lung cancer
NCT ID NCT05393466
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental pill, BPI-361175, in 30 adults with advanced non-small cell lung cancer that has specific EGFR mutations and has stopped responding to standard treatments. The goal is to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants will take the pill and be monitored for side effects and cancer progression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted pill keep lung cancer from returning?
- Seeing Cancer's hidden markers: a new PET tracer could reveal who responds to targeted therapy
- Lab-Made immune protein takes on advanced cancers in first human test
- Experimental combo for lung cancer shows promise but study cut short
- New study tracks how well a targeted lung cancer drug works in everyday clinics
- New 4D scan could sharpen lung cancer radiation